Tag Archives: 2019
#437791 Is the Pandemic Spurring a Robot ...
“Are robots really destined to take over restaurant kitchens?” This was the headline of an article published by Eater four years ago. One of the experts interviewed was Siddhartha Srinivasa, at the time professor of the Robotics Institute at Carnegie Mellon University and currently director of Robotics and AI for Amazon. He said, “I’d love to make robots unsexy. It’s weird to say this, but when something becomes unsexy, it means that it works so well that you don’t have to think about it. You don’t stare at your dishwasher as it washes your dishes in fascination, because you know it’s gonna work every time… I want to get robots to that stage of reliability.”
Have we managed to get there over the last four years? Are robots unsexy yet? And how has the pandemic changed the trajectory of automation across industries?
The Covid Effect
The pandemic has had a massive economic impact all over the world, and one of the problems faced by many companies has been keeping their businesses running without putting employees at risk of infection. Many organizations are seeking to remain operational in the short term by automating tasks that would otherwise be carried out by humans. According to Digital Trends, since the start of the pandemic we have seen a significant increase in automation efforts in manufacturing, meat packing, grocery stores and more. In a June survey, 44 percent of corporate financial officers said they were considering more automation in response to coronavirus.
MIT economist David Autor described the economic crisis and the Covid-19 pandemic as “an event that forces automation.” But he added that Covid-19 created a kind of disruption that has forced automation in sectors and activities with a shortage of workers, while at the same time there has been no reduction in demand. This hasn’t taken place in hospitality, where demand has practically disappeared, but it is still present in agriculture and distribution. The latter is being altered by the rapid growth of e-commerce, with more efficient and automated warehouses that can provide better service.
China Leads the Way
China is currently in a unique position to lead the world’s automation economy. Although the country boasts a huge workforce, labor costs have multiplied by 10 over the past 20 years. As the world’s factory, China has a strong incentive to automate its manufacturing sector, which enjoys a solid leadership in high quality products. China is currently the largest and fastest-growing market in the world for industrial robotics, with a 21 percent increase up to $5.4 billion in 2019. This represents one third of global sales. As a result, Chinese companies are developing a significant advantage in terms of learning to work with metallic colleagues.
The reasons behind this Asian dominance are evident: the population has a greater capacity and need for tech adoption. A large percentage of the population will soon be of retirement age, without an equivalent younger demographic to replace it, leading to a pressing need to adopt automation in the short term.
China is well ahead of other countries in restaurant automation. As reported in Bloomberg, in early 2020 UBS Group AG conducted a survey of over 13,000 consumers in different countries and found that 64 percent of Chinese participants had ordered meals through their phones at least once a week, compared to a mere 17 percent in the US. As digital ordering gains ground, robot waiters and chefs are likely not far behind. The West harbors a mistrust towards non-humans that the East does not.
The Robot Evolution
The pandemic was a perfect excuse for robots to replace us. But despite the hype around this idea, robots have mostly disappointed during the pandemic.
Just over 66 different kinds of “social” robots have been piloted in hospitals, health centers, airports, office buildings, and other public and private spaces in response to the pandemic, according to a study from researchers at Pompeu Fabra University (Barcelona, Spain). Their survey looked at 195 robot deployments across 35 countries including China, the US, Thailand, and Hong Kong.
But if the “robot revolution” is a movement in which automation, robotics, and artificial intelligence proliferate through the value chain of various industries, bringing a paradigm shift in how we produce, consume, and distribute products—it hasn’t happened yet.
But there’s a more nuanced answer: rather than a revolution, we’re seeing an incremental robot evolution. It’s a trend that will likely accelerate over the next five years, particularly when 5G takes center stage and robotics as a field leaves behind imitation and evolves independently.
Automation Anxiety
Why don’t we finally welcome the long-promised robotic takeover? Despite progress in AI and increased adoption of industrial robots, consumer-facing robotic products are not nearly as ubiquitous as popular culture predicted decades ago. As Amara’s Law says: “We tend to overestimate the effect of a technology in the short run and underestimate the effect in the long run.” It seems we are living through the Gartner hype cycle.
People have a complicated relationship with robots, torn between admiring them, fearing them, rejecting them, and even boycotting them, as has happened in the automobile industry.
Retail robot in a Walmart store. Credit: Bossa Nova Robotics
Walmart terminated its contract with Bossa Nova and withdrew its 1,000 inventory robots from its stores because the company was concerned about how shoppers were reacting to seeing the six-foot robots in the aisles.
With road blocks like this, will the World Economic Forum’s prediction of almost half of tasks being carried out by machines by 2025 come to pass?
At the rate we’re going, it seems unlikely, even with the boost in automation caused by the pandemic. Robotics will continue to advance its capabilities, and will take over more human jobs as it does so, but it’s unlikely we’ll hit a dramatic inflection point that could be described as a “revolution.” Instead, the robot evolution will happen the way most societal change does: incrementally, with time for people to adapt both practically and psychologically.
For now though, robots are still pretty sexy.
Image Credit: charles taylor / Shutterstock.com Continue reading
Posted in Human Robots
#437753 iRobot’s New Education Robot Makes ...
iRobot has been on a major push into education robots recently. They acquired Root Robotics in 2019, and earlier this year, launched an online simulator and associated curriculum designed to work in tandem with physical Root robots. The original Root was intended to be a classroom robot, with one of its key features being the ability to stick to (and operate on) magnetic virtual surfaces, like whiteboards. And as a classroom robot, at $200, it’s relatively affordable, if you can buy one or two and have groups of kids share them.
For kids who are more focused on learning at home, though, $200 is a lot for a robot that doesn't even keep your floors clean. And as nice as it is to have a free simulator, any kid will tell you that it’s way cooler to have a real robot to mess around with. Today, iRobot is announcing a new version of Root that’s been redesigned for home use, with a $129 price that makes it significantly more accessible to folks outside of the classroom.
The Root rt0 is a second version of the Root robot—the more expensive, education-grade Root rt1 is still available. To bring the cost down, the rt0 is missing some features that you can still find in the rt1. Specifically, you don’t get the internal magnets to stick the robot to vertical surfaces, there are no cliff sensors, and you don’t get a color scanner or an eraser. But for home use, the internal magnets are probably not necessary anyway, and the rest of that stuff seems like a fair compromise for a cost reduction of 30 percent.
Photo: iRobot
One of the new accessories for the iRobot Root rt0 is a “Brick Top” that snaps onto the upper face the robot via magnets. The accessory can be used with LEGOs and other LEGO-compatible bricks, opening up an enormous amount of customization.
It’s not all just taking away, though. There’s also a new $20 accessory, a LEGO-ish “Brick Top” that snaps onto the upper face of Root (either version) via magnets. The plate can be used with LEGO bricks and other LEGO-compatible things. This opens up an enormous amount of customization, and it’s for more than just decoration, since Root rt0 has the ability to interact with whatever’s on top of it via its actuated marker. Root can move the marker up and down, the idea being that you can programmatically turn lines on and off. By replacing the marker with a plastic thingy that sticks up through the body of the robot, the marker up/down command can be used to actuate something on the brick top. In the video, that’s what triggers the catapult.
Photo: iRobot
By attaching a marker, you can program Root to draw. The robot has a motor that can move the marker up and down.
This less expensive version of Root still has access to the online simulator, as well as the multi-level coding interface that allows kids to seamlessly transition through multiple levels of coding complexity, from graphical to text. There’s a new Android app coming out today, and you can access everything through web-based apps on Chrome OS, Windows and macOS, as well as on iOS. iRobot tells us that they’ve also recently expanded their online learning library full of Root-based educational activities. In particular, they’ve added a new category on “Social Emotional Learning,” the goal of which is to help kids develop things like social awareness, self-management, decision making, and relationship skills. We’re not quite sure how you teach those things with a little hexagonal robot, but we like that iRobot is giving it a try.
Root coding robots are designed for kids age 6 and up, ships for free, and is available now.
[ iRobot Root ] Continue reading
Posted in Human Robots
#437673 Can AI and Automation Deliver a COVID-19 ...
Illustration: Marysia Machulska
Within moments of meeting each other at a conference last year, Nathan Collins and Yann Gaston-Mathé began devising a plan to work together. Gaston-Mathé runs a startup that applies automated software to the design of new drug candidates. Collins leads a team that uses an automated chemistry platform to synthesize new drug candidates.
“There was an obvious synergy between their technology and ours,” recalls Gaston-Mathé, CEO and cofounder of Paris-based Iktos.
In late 2019, the pair launched a project to create a brand-new antiviral drug that would block a specific protein exploited by influenza viruses. Then the COVID-19 pandemic erupted across the world stage, and Gaston-Mathé and Collins learned that the viral culprit, SARS-CoV-2, relied on a protein that was 97 percent similar to their influenza protein. The partners pivoted.
Their companies are just two of hundreds of biotech firms eager to overhaul the drug-discovery process, often with the aid of artificial intelligence (AI) tools. The first set of antiviral drugs to treat COVID-19 will likely come from sifting through existing drugs. Remdesivir, for example, was originally developed to treat Ebola, and it has been shown to speed the recovery of hospitalized COVID-19 patients. But a drug made for one condition often has side effects and limited potency when applied to another. If researchers can produce an antiviral that specifically targets SARS-CoV-2, the drug would likely be safer and more effective than a repurposed drug.
There’s one big problem: Traditional drug discovery is far too slow to react to a pandemic. Designing a drug from scratch typically takes three to five years—and that’s before human clinical trials. “Our goal, with the combination of AI and automation, is to reduce that down to six months or less,” says Collins, who is chief strategy officer at SRI Biosciences, a division of the Silicon Valley research nonprofit SRI International. “We want to get this to be very, very fast.”
That sentiment is shared by small biotech firms and big pharmaceutical companies alike, many of which are now ramping up automated technologies backed by supercomputing power to predict, design, and test new antivirals—for this pandemic as well as the next—with unprecedented speed and scope.
“The entire industry is embracing these tools,” says Kara Carter, president of the International Society for Antiviral Research and executive vice president of infectious disease at Evotec, a drug-discovery company in Hamburg. “Not only do we need [new antivirals] to treat the SARS-CoV-2 infection in the population, which is probably here to stay, but we’ll also need them to treat future agents that arrive.”
There are currentlyabout 200 known viruses that infect humans. Although viruses represent less than 14 percent of all known human pathogens, they make up two-thirds of all new human pathogens discovered since 1980.
Antiviral drugs are fundamentally different from vaccines, which teach a person’s immune system to mount a defense against a viral invader, and antibody treatments, which enhance the body’s immune response. By contrast, antivirals are chemical compounds that directly block a virus after a person has become infected. They do this by binding to specific proteins and preventing them from functioning, so that the virus cannot copy itself or enter or exit a cell.
The SARS-CoV-2 virus has an estimated 25 to 29 proteins, but not all of them are suitable drug targets. Researchers are investigating, among other targets, the virus’s exterior spike protein, which binds to a receptor on a human cell; two scissorlike enzymes, called proteases, that cut up long strings of viral proteins into functional pieces inside the cell; and a polymerase complex that makes the cell churn out copies of the virus’s genetic material, in the form of single-stranded RNA.
But it’s not enough for a drug candidate to simply attach to a target protein. Chemists also consider how tightly the compound binds to its target, whether it binds to other things as well, how quickly it metabolizes in the body, and so on. A drug candidate may have 10 to 20 such objectives. “Very often those objectives can appear to be anticorrelated or contradictory with each other,” says Gaston-Mathé.
Compared with antibiotics, antiviral drug discovery has proceeded at a snail’s pace. Scientists advanced from isolating the first antibacterial molecules in 1910 to developing an arsenal of powerful antibiotics by 1944. By contrast, it took until 1951 for researchers to be able to routinely grow large amounts of virus particles in cells in a dish, a breakthrough that earned the inventors a Nobel Prize in Medicine in 1954.
And the lag between the discovery of a virus and the creation of a treatment can be heartbreaking. According to the World Health Organization, 71 million people worldwide have chronic hepatitis C, a major cause of liver cancer. The virus that causes the infection was discovered in 1989, but effective antiviral drugs didn’t hit the market until 2014.
While many antibiotics work on a range of microbes, most antivirals are highly specific to a single virus—what those in the business call “one bug, one drug.” It takes a detailed understanding of a virus to develop an antiviral against it, says Che Colpitts, a virologist at Queen’s University, in Canada, who works on antivirals against RNA viruses. “When a new virus emerges, like SARS-CoV-2, we’re at a big disadvantage.”
Making drugs to stop viruses is hard for three main reasons. First, viruses are the Spartans of the pathogen world: They’re frugal, brutal, and expert at evading the human immune system. About 20 to 250 nanometers in diameter, viruses rely on just a few parts to operate, hijacking host cells to reproduce and often destroying those cells upon departure. They employ tricks to camouflage their presence from the host’s immune system, including preventing infected cells from sending out molecular distress beacons. “Viruses are really small, so they only have a few components, so there’s not that many drug targets available to start with,” says Colpitts.
Second, viruses replicate quickly, typically doubling in number in hours or days. This constant copying of their genetic material enables viruses to evolve quickly, producing mutations able to sidestep drug effects. The virus that causes AIDS soon develops resistance when exposed to a single drug. That’s why a cocktail of antiviral drugs is used to treat HIV infection.
Finally, unlike bacteria, which can exist independently outside human cells, viruses invade human cells to propagate, so any drug designed to eliminate a virus needs to spare the host cell. A drug that fails to distinguish between a virus and a cell can cause serious side effects. “Discriminating between the two is really quite difficult,” says Evotec’s Carter, who has worked in antiviral drug discovery for over three decades.
And then there’s the money barrier. Developing antivirals is rarely profitable. Health-policy researchers at the London School of Economics recently estimated that the average cost of developing a new drug is US $1 billion, and up to $2.8 billion for cancer and other specialty drugs. Because antivirals are usually taken for only short periods of time or during short outbreaks of disease, companies rarely recoup what they spent developing the drug, much less turn a profit, says Carter.
To change the status quo, drug discovery needs fresh approaches that leverage new technologies, rather than incremental improvements, says Christian Tidona, managing director of BioMed X, an independent research institute in Heidelberg, Germany. “We need breakthroughs.”
Putting Drug Development on Autopilot
Earlier this year, SRI Biosciences and Iktos began collaborating on a way to use artificial intelligence and automated chemistry to rapidly identify new drugs to target the COVID-19 virus. Within four months, they had designed and synthesized a first round of antiviral candidates. Here’s how they’re doing it.
1/5
STEP 1: Iktos’s AI platform uses deep-learning algorithms in an iterative process to come up with new molecular structures likely to bind to and disable a specific coronavirus protein. Illustrations: Chris Philpot
2/5
STEP 2: SRI Biosciences’s SynFini system is a three-part automated chemistry suite for producing new compounds. Starting with a target compound from Iktos, SynRoute uses machine learning to analyze and optimize routes for creating that compound, with results in about 10 seconds. It prioritizes routes based on cost, likelihood of success, and ease of implementation.
3/5
STEP 3: SynJet, an automated inkjet printer platform, tests the routes by printing out tiny quantities of chemical ingredients to see how they react. If the right compound is produced, the platform tests it.
4/5
STEP 4: AutoSyn, an automated tabletop chemical plant, synthesizes milligrams to grams of the desired compound for further testing. Computer-selected “maps” dictate paths through the plant’s modular components.
5/5
STEP 5: The most promising compounds are tested against live virus samples.
Previous
Next
Iktos’s AI platform was created by a medicinal chemist and an AI expert. To tackle SARS-CoV-2, the company used generative models—deep-learning algorithms that generate new data—to “imagine” molecular structures with a good chance of disabling a key coronavirus protein.
For a new drug target, the software proposes and evaluates roughly 1 million compounds, says Gaston-Mathé. It’s an iterative process: At each step, the system generates 100 virtual compounds, which are tested in silico with predictive models to see how closely they meet the objectives. The test results are then used to design the next batch of compounds. “It’s like we have a very, very fast chemist who is designing compounds, testing compounds, getting back the data, then designing another batch of compounds,” he says.
The computer isn’t as smart as a human chemist, Gaston-Mathé notes, but it’s much faster, so it can explore far more of what people in the field call “chemical space”—the set of all possible organic compounds. Unexplored chemical space is huge: Biochemists estimate that there are at least 1063 possible druglike molecules, and that 99.9 percent of all possible small molecules or compounds have never been synthesized.
Still, designing a chemical compound isn’t the hardest part of creating a new drug. After a drug candidate is designed, it must be synthesized, and the highly manual process for synthesizing a new chemical hasn’t changed much in 200 years. It can take days to plan a synthesis process and then months to years to optimize it for manufacture.
That’s why Gaston-Mathé was eager to send Iktos’s AI-generated designs to Collins’s team at SRI Biosciences. With $13.8 million from the Defense Advanced Research Projects Agency, SRI Biosciences spent the last four years automating the synthesis process. The company’s automated suite of three technologies, called SynFini, can produce new chemical compounds in just hours or days, says Collins.
First, machine-learning software devises possible routes for making a desired molecule. Next, an inkjet printer platform tests the routes by printing out and mixing tiny quantities of chemical ingredients to see how they react with one another; if the right compound is produced, the platform runs tests on it. Finally, a tabletop chemical plant synthesizes milligrams to grams of the desired compound.
Less than four months after Iktos and SRI Biosciences announced their collaboration, they had designed and synthesized a first round of antiviral candidates for SARS-CoV-2. Now they’re testing how well the compounds work on actual samples of the virus.
Out of 10
63 possible druglike molecules, 99.9 percent have never been synthesized.
Theirs isn’t the only collaborationapplying new tools to drug discovery. In late March, Alex Zhavoronkov, CEO of Hong Kong–based Insilico Medicine, came across a YouTube video showing three virtual-reality avatars positioning colorful, sticklike fragments in the side of a bulbous blue protein. The three researchers were using VR to explore how compounds might bind to a SARS-CoV-2 enzyme. Zhavoronkov contacted the startup that created the simulation—Nanome, in San Diego—and invited it to examine Insilico’s AI-generated molecules in virtual reality.
Insilico runs an AI platform that uses biological data to train deep-learning algorithms, then uses those algorithms to identify molecules with druglike features that will likely bind to a protein target. A four-day training sprint in late January yielded 100 molecules that appear to bind to an important SARS-CoV-2 protease. The company recently began synthesizing some of those molecules for laboratory testing.
Nanome’s VR software, meanwhile, allows researchers to import a molecular structure, then view and manipulate it on the scale of individual atoms. Like human chess players who use computer programs to explore potential moves, chemists can use VR to predict how to make molecules more druglike, says Nanome CEO Steve McCloskey. “The tighter the interface between the human and the computer, the more information goes both ways,” he says.
Zhavoronkov sent data about several of Insilico’s compounds to Nanome, which re-created them in VR. Nanome’s chemist demonstrated chemical tweaks to potentially improve each compound. “It was a very good experience,” says Zhavoronkov.
Meanwhile, in March, Takeda Pharmaceutical Co., of Japan, invited Schrödinger, a New York–based company that develops chemical-simulation software, to join an alliance working on antivirals. Schrödinger’s AI focuses on the physics of how proteins interact with small molecules and one another.
The software sifts through billions of molecules per week to predict a compound’s properties, and it optimizes for multiple desired properties simultaneously, says Karen Akinsanya, chief biomedical scientist and head of discovery R&D at Schrödinger. “There’s a huge sense of urgency here to come up with a potent molecule, but also to come up with molecules that are going to be well tolerated” by the body, she says. Drug developers are seeking compounds that can be broadly used and easily administered, such as an oral drug rather than an intravenous drug, she adds.
Schrödinger evaluated four protein targets and performed virtual screens for two of them, a computing-intensive process. In June, Google Cloud donated the equivalent of 16 million hours of Nvidia GPU time for the company’s calculations. Next, the alliance’s drug companies will synthesize and test the most promising compounds identified by the virtual screens.
Other companies, including Amazon Web Services, IBM, and Intel, as well as several U.S. national labs are also donating time and resources to the Covid-19 High Performance Computing Consortium. The consortium is supporting 87 projects, which now have access to 6.8 million CPU cores, 50,000 GPUs, and 600 petaflops of computational resources.
While advanced technologies could transform early drug discovery, any new drug candidate still has a long road after that. It must be tested in animals, manufactured in large batches for clinical trials, then tested in a series of trials that, for antivirals, lasts an average of seven years.
In May, the BioMed X Institute in Germany launched a five-year project to build a Rapid Antiviral Response Platform, which would speed drug discovery all the way through manufacturing for clinical trials. The €40 million ($47 million) project, backed by drug companies, will identify outside-the-box proposals from young scientists, then provide space and funding to develop their ideas.
“We’ll focus on technologies that allow us to go from identification of a new virus to 10,000 doses of a novel potential therapeutic ready for trials in less than six months,” says BioMed X’s Tidona, who leads the project.
While a vaccine will likely arrive long before a bespoke antiviral does, experts expect COVID-19 to be with us for a long time, so the effort to develop a direct-acting, potent antiviral continues. Plus, having new antivirals—and tools to rapidly create more—can only help us prepare for the next pandemic, whether it comes next month or in another 102 years.
“We’ve got to start thinking differently about how to be more responsive to these kinds of threats,” says Collins. “It’s pushing us out of our comfort zones.”
This article appears in the October 2020 print issue as “Automating Antivirals.” Continue reading
Posted in Human Robots